{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:53Z","timestamp":1790662133054,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research (CIHR)","doi-asserted-by":"publisher","award":["179883"],"award-info":[{"award-number":["179883"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Waters Corporation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.cca.2015.11.018","type":"journal-article","created":{"date-parts":[[2015,11,22]],"date-time":"2015-11-22T01:50:13Z","timestamp":1448157013000},"page":"191-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients"],"prefix":"10.1016","volume":"452","author":[{"given":"Mona","family":"Abaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2015.11.018_bb0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.cca.2015.11.018_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2015.11.018_bb0015","unstructured":"HGMD. Human gene mutation database. http:\/\/www.hgmd.org\/. (Updated 2014)."},{"issue":"5","key":"10.1016\/j.cca.2015.11.018_bb0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","article-title":"Prevalence of symptoms in female Fabry disease patients: a case\u2013control survey","volume":"35","author":"Bouwman","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"19","key":"10.1016\/j.cca.2015.11.018_bb0025","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. yin and yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J."},{"issue":"457","key":"10.1016\/j.cca.2015.11.018_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"issue":"6","key":"10.1016\/j.cca.2015.11.018_bb0035","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.061020598","article-title":"Preselective gene therapy for Fabry disease","volume":"98","author":"Qin","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.cca.2015.11.018_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10545-014-9758-8","article-title":"The consequences of genetic and pharmacologic reduction in sphingolipid synthesis","volume":"38","author":"Schiffmann","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.cca.2015.11.018_bb0050","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.cca.2015.11.018_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymgme.2009.11.001","article-title":"Baseline characteristics of patients enrolled in the Canadian Fabry disease initiative","volume":"99","author":"Sirrs","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.cca.2015.11.018_bb0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0065","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cca.2015.11.018_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.cca.2015.11.018_bb0075","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"issue":"23\u201324","key":"10.1016\/j.cca.2015.11.018_bb0080","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.cca.2015.11.018_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.cca.2015.11.018_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15353\/cjo.74.550","article-title":"Improved ways to screen for patients with Fabry disease, involving optometry in a multidisciplinary approach","volume":"74","author":"Michaud","year":"2012","journal-title":"Can. J. Optom."},{"key":"10.1016\/j.cca.2015.11.018_bb0095","series-title":"Fabry Disease: Perspectives from 5Years of FOS","article-title":"Biochemical and Genetic Diagnosis of Fabry Disease","author":"Winchester","year":"2006"},{"key":"10.1016\/j.cca.2015.11.018_bb0100","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweeley","year":"1963","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cca.2015.11.018_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J. Am. Soc. Mass Spectrom."},{"issue":"1","key":"10.1016\/j.cca.2015.11.018_bb0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000394","article-title":"Risk of death in heart disease is associated with elevated urinary globotriaosylceramide","volume":"3","author":"Schiffmann","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.cca.2015.11.018_bb0120","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2015.11.018_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC\u2013MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"7","key":"10.1016\/j.cca.2015.11.018_bb0130","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.cca.2015.11.018_bb0135","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.cca.2015.11.018_bb0140","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0145","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"issue":"447","key":"10.1016\/j.cca.2015.11.018_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.cca.2015.11.018_bb0155","first-page":"195","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438C","author":"Auray-Blais","year":"2014","journal-title":"Clin. Chim. Acta"},{"issue":"19","key":"10.1016\/j.cca.2015.11.018_bb0160","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"issue":"19","key":"10.1016\/j.cca.2015.11.018_bb0165","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.cca.2015.11.018_bb0170","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1515\/CCLM.2007.341","article-title":"Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine","volume":"45","author":"Finkelstein","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"issue":"12","key":"10.1016\/j.cca.2015.11.018_bb0175","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.bmc.2011.01.046","article-title":"Inhibitors of histone demethylases","volume":"19","author":"Lohse","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.cca.2015.11.018_bb0180","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1021\/tx700174w","article-title":"Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases","volume":"20","author":"Bai","year":"2007","journal-title":"Chem. Res. Toxicol."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nchembio.767","article-title":"Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin","volume":"8","author":"Patti","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.cca.2015.11.018_bb0190","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1194\/jlr.D700041-JLR200","article-title":"Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics","volume":"49","author":"Matyash","year":"2008","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb3\/creatinine biomarkers for Fabry disease: Issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.cca.2015.11.018_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol. Genet. Metab."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115300553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115300553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T16:14:43Z","timestamp":1653581683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898115300553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":40,"alternative-id":["S0009898115300553"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2015.11.018","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2015.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}